Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dianthus Therapeutics ( (DNTH) ) has provided an announcement.
On September 8, 2025, Dianthus Therapeutics announced positive top-line data from its Phase 2 MaGic trial for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). The trial demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, with a favorable safety profile. These results support the potential best-in-class profile of claseprubart and bolster confidence in future clinical programs.
The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
Spark’s Take on DNTH Stock
According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.
The overall stock score for Dianthus Therapeutics is primarily impacted by its financial performance, which is concerning due to declining revenues and substantial losses. Technical analysis provides some positive signals with short-term bullish momentum, but the valuation remains unattractive due to negative profitability. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on DNTH stock, click here.
More about Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics to treat severe autoimmune diseases.
Average Trading Volume: 361,189
Technical Sentiment Signal: Buy
Current Market Cap: $853M
See more data about DNTH stock on TipRanks’ Stock Analysis page.